Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.68 USD | -0.35% | +5.51% | +19.89% |
04-16 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
04-11 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.89% | 704M | |
+10.44% | 106B | |
+0.82% | 104B | |
+6.72% | 23.25B | |
-13.89% | 22.5B | |
-6.64% | 18.7B | |
-37.26% | 17.95B | |
-10.98% | 16.99B | |
+8.67% | 14.26B | |
+41.08% | 12.76B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- AnaptysBio to Halt Imsidolimab Development for Acne After Trial; Shares Plunge 13% After Hours